Allogene Therapeutics, Inc.: Citadel Securities GP LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Citadel Securities GP LLC disclosed a stake exceeding 5% in Allogene Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001104659-26-128279). The exact share count and percentage were not specified in the filing headline. The disclosure signals heightened institutional interest in the clinical-stage cell therapy developer. Investors will watch for further detail on the position's size and any subsequent 13G amendments.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Citadel Securities GP LLC, Allogene Therapeutics, Inc.